Integrated Safety Analysis of Filgotinib in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis Over a Treatment Duration of up to 5 Years
Long-term filgotinib treatment was well tolerated at 200 mg and 100 mg in Japanese patients with RA over up to 5 years, confirming previous global analyses.
Authors
- Hisaaki Isaji (ORCID: https://orcid.org/0000-0001-8544-4177)
- Katrien Van Beneden (ORCID: https://orcid.org/0009-0001-2004-7653)
- Akira Kondo (ORCID: https://orcid.org/0000-0001-9808-6989)
- Yoshiya Tanaka
- Tsutomu Takeuchi
- Roger Mutter
Institutions
- University of Occupational and Environmental Health Japan (JP)
- Alfasigma (Italy) (IT)
- Gilead Sciences (United States) (US)
- Saitama Medical University (JP)
Publication Details
- Journal
- Modern Rheumatology
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1093/mr/roag029
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00